Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy - The P-SELECT trial (WJOG10617G) - A randomised phase II trial by the West Japan Oncology Group

Kenro Hirata, Yasuo Hamamoto, Masahiko Ando, Chiyo K. Imamura, Kenichi Yoshimura, Kentaro Yamazaki, Shuichi Hironaka, Kei Muro

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy - The P-SELECT trial (WJOG10617G) - A randomised phase II trial by the West Japan Oncology Group'. Together they form a unique fingerprint.

Medicine & Life Sciences